This site is intended for health professionals only
Thursday 23 May 2019
Share |

Topic: Cost effectiveness

April 15, 2016
Available in new presentation strength of 0.1mg/ml to maximise accuracy and flexibility of dosing

Martindale Pharma, the UK-based leading international specialty pharmaceutical company, announced the UK launch of Phenylephrine, a new strength of the selective vasopressor drug for the treatment of hypotension associated with anaesthesia. Phenylephrine will be available in a 10ml ampoule at a strength of 0.1mg/ml.
 

January 11, 2016
In a study of 397 patients with ulcerative colitis and Crohn’s disease, 93 patients (23%) were switched to a biosimilar infliximab from the reference infliximab, representing the largest group of switch patients studied to date in inflammatory bowel diseases
  • In a study of 397 patients with ulcerative colitis and Crohn’s disease, 93 patients (23%) were switched to a biosimilar infliximab from the reference infliximab, representing the largest group of switch patients studied to date in inflammatory bowel diseases (IBD)1
     
January 5, 2016
The ‘traditional’ drug cupboard makes way for intelligent and automated medicine storage cabinet with impressive results
October 16, 2015
VIEKIRAX + EXVIERA confirmed as cost effective treatment for adults with genotype 1 chronic hepatitis C virus (HCV) infection, including those with HIV/HCV co-infection, in NICE Final Appraisal Determination (FAD)

An estimated 214,000 people in the UK are chronically infected with hepatitis C (1), of which only an estimated 3% receive treatment in England each year (2).

 

August 10, 2015
A distinguished panel convened to discuss the ‘Challenges of Modern Medicine’ during a lively and stimulating satellite symposium sponsored by Accord Healthcare at the 20th EAHP conference in Hamburg, Germany, on 25 March 2015

 

May 28, 2015
To provide higher quality clinical pharmacy services at a tertiary health centre, a clinical pharmacy department, based on a theoretical model, was formally established and organisational changes were feasible and financially justified

 

May 19, 2015
Data presented from the CDI Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes. Compared to traditional broad-spectrum antibiotics, first-line use of fidaxomicin, a targeted treatment, in all CDI patients provides improved outcomes in terms of recurrence rate, all-cause mortality and cost effectiveness, compared to use in selected patients only. (8) CDI is associated with high-mortality (5,6,7) and cost burden, (9) therefore reducing the incidence and recurrence of CDI is a priority for clinicians, payers and health authorities alike.
March 26, 2015
The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost effectiveness of new drugs; this hampers the value-assessment and decision-making processes.

The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost–effectiveness of new drugs; this hampers the value-assessment and decision-making processes.
 

March 26, 2015
The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost effectiveness of new drugs; this hampers the value-assessment and decision-making processes.

The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost–effectiveness of new drugs; this hampers the value-assessment and decision-making processes.
 

March 3, 2015
• The European Medicines Agency has determined that Remsima, a biosimilar, is comparable to the reference product Remicade® in terms of safety, efficacy and quality across all approved indications • Remsima is expected to cost less than the reference product; these savings could allow more patients with inflammatory autoimmune diseases to access monoclonal antibody therapy • Biosimilar monoclonal antibodies are expected to save European healthcare systems between €1.8 and €20.4 billion between 2007 and 2020 (1)

•    The European Medicines Agency has determined that Remsima, a biosimilar, is comparable to the reference product Remicade® in terms of safety, efficacy and quality across all approved indications
•    Remsima is expected to cost less than the reference product; these savings could allow more patients with inflammatory autoimmune diseases to access monoclonal antibody therapy

February 25, 2015
Researchers from the Medical Research Council Clinical Trials Unit (MRC CTU) and Public Health England have presented results at a conference in Seattle, Washington, indicating that pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay and other men who have sex with men in England.

Researchers from the Medical Research Council Clinical Trials Unit (MRC CTU) and Public Health England have presented results at a conference in Seattle, Washington, indicating that pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay and other men who have sex with men in England.

 

February 20, 2015
Ferring Pharmaceuticals announced the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient.

Ferring Pharmaceuticals announced the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient.

 

 

January 29, 2015
Accord Healthcare is pleased to announce the launch of their first European approved biopharmaceutical product Accofil®, indicated for the treatment of chemotherapy induced neutropenia.

Accord Healthcare is pleased to announce the launch of their first European approved biopharmaceutical product Accofil®, indicated for the treatment of chemotherapy induced neutropenia.

 

Accofil® is a biopharmaceutical product with the same range of indications as Neupogen® (filgrastim) and will offer patients comparable quality, safety and efficacy combined with cost-effectiveness.

 

Therapeutic Indications (1)
Accofil® is indicated for the treatment of:

January 27, 2015
The National Institute for Health and Care Excellence (NICE) issued its Final Appraisal Determination (FAD) recommending Xarelto 2.5mg twice daily as an effective treatment option for preventing secondary events – such as death, heart attack or stroke – following acute coronary syndrome (ACS) in patients with elevated cardiac biomarkers, without prior stroke or transient ischaemic attack (TIA). (1) The FAD is the final phase in a multi-step review process by NICE and recognises the improved patient outcomes using Xarelto as a treatment option on top of dual antiplatelet therapy;* publication of guidance is expected to follow in Q1 2015.
January 16, 2015
A new hepatitis C medicine, called simeprevir, is now available that the NHS in England will only pay for if patients successfully clear the virus. The ‘pay if you clear’ reimbursement scheme, agreed with NHS England, refunds the cost of simeprevir for patients who do not successfully clear the virus after 12 weeks.

A new hepatitis C medicine, called simeprevir, is now available that the NHS in England will only pay for if patients successfully clear the virus. The ‘pay if you clear’ reimbursement scheme, agreed with NHS England, refunds the cost of simeprevir for patients who do not successfully clear the virus after 12 weeks.

January 16, 2015
The Minister for Health and Social Services in Wales ratified the positive recommendation from the All Wales Medicines Strategy Group (AWMSG) that Iclusig® (ponatinib) is a cost effective treatment option for use within its licenced indication in chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia.

The Minister for Health and Social Services in Wales ratified the positive recommendation from the All Wales Medicines Strategy Group (AWMSG) that Iclusig® (ponatinib) is a cost effective treatment option for use within its licenced indication in chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia.

November 26, 2014
New analysis from a unique real-world study demonstrates that first-line use of fidaxomicin, is clinically effective in reducing recurrence rates and lowering mortality, and provides cost savings for the treatment of potentially fatal Clostridium difficile infection (CDI).

New analysis from a unique real-world study demonstrates that first-line use of fidaxomicin, is clinically effective in reducing recurrence rates and lowering mortality, and provides cost savings for the treatment of potentially fatal Clostridium difficile infection (CDI). (2)
 

November 18, 2014
EPS has released 3 new styles of oral syringes. All were designed with METRIC-ONLY markings, meeting the latest ISMP recommendations. Eight sizes, ranging from 0.5ml to 60ml, are immediately available. Syringes are stocked in either clear – with orange or blue graduations – or in light-protecting, ultraviolet inhibiting amber with white graduations.

EPS has released 3 new styles of oral syringes.  All were designed with METRIC-ONLY markings, meeting the latest ISMP recommendations.  Eight sizes, ranging from 0.5ml to 60ml, are immediately available.  Syringes are stocked in either clear – with orange or blue graduations – or in light-protecting, ultraviolet inhibiting amber with white graduations.   

October 21, 2014
Bayer HealthCare is delighted to announce that the innovative drug, Adempas, has received a Prix Galien Award – a High Commendation at the 2014 ceremony at The House of Commons. The bi-annual awards are designed to recognise the significant contribution the pharmaceutical industry makes in clinical research and drug development.

Bayer HealthCare is delighted to announce that the innovative drug, Adempas, has received a Prix Galien Award – a High Commendation at the 2014 ceremony at The House of Commons. The bi-annual awards are designed to recognise the significant contribution the pharmaceutical industry makes in clinical research and drug development.

October 10, 2014
Bayer HealthCare announces it is pleased that the National Institute for Health and Care Excellence (NICE) clinical guideline for the management of Multiple Sclerosis (MS) in primary and secondary care (CG186) recognises the multi-faceted nature of the disease and the complex needs of people with MS. Bayer welcomes the recommendation that MS patients should have a single point of contact and a comprehensive annual review but are disappointed that the guideline did not recommend Sativex® as a treatment option for moderate to severe spasticity.

Bayer HealthCare announces it is pleased that the National Institute for Health and Care Excellence (NICE) clinical guideline for the management of Multiple Sclerosis (MS) in primary and secondary care (CG186) recognises the multi-faceted nature of the disease and the complex needs of people with MS. Bayer welcomes the recommendation that MS patients should have a single point of contact and a comprehensive annual review but are disappointed that the guideline did not recommend Sativex® as a treatment option for moderate to severe spasticity. (1)
 

September 17, 2014
New figures released show the cost of managing hypoglycaemia in the UK could be £363.6 million per year (£235.6 million for severe episodes and £128 million for non-severe). The economic burden of hypoglycaemia, calculated using the Local Impact of Hypoglycaemia Tool (LIHT), was presented at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting.

New figures released show the cost of managing hypoglycaemia in the UK could be £363.6 million per year (£235.6 million for severe episodes and £128 million for non-severe). The economic burden of hypoglycaemia, calculated using the Local Impact of Hypoglycaemia Tool (LIHT), was presented at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting.

 

September 10, 2014
A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (€1.5 million / £1.2 million).

A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (€1.5 million / £1.2 million). (1)

The cost reductions are based on a health economic model from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study, presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C

July 23, 2014
“There is no way health will be delivered without funding in technology innovation” was the message for CTOs at the Birmingham Science City ideasforlife CTO Group breakfast meet, hosted by SCC.

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine